179 related articles for article (PubMed ID: 37693908)
1. An international comparative analysis and roadmap to sustainable biosimilar markets.
Alnaqbi KA; Bellanger A; Brill A; Castañeda-Hernández G; Clopés Estela A; Delgado Sánchez O; García-Alfonso P; Gyger P; Heinrich D; Hezard G; Kakehasi A; Koehn C; Mariotte O; Mennini F; Mayra Pérez-Tapia S; Pistollato M; Saada R; Sasaki T; Tambassis G; Thill M; Werutsky G; Wilsdon T; Simoens S
Front Pharmacol; 2023; 14():1188368. PubMed ID: 37693908
[No Abstract] [Full Text] [Related]
2. Policies for biosimilar uptake in Europe: An overview.
Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
[TBL] [Abstract][Full Text] [Related]
3. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market.
Río-Álvarez I; Cruz-Martos E
Expert Opin Biol Ther; 2024 Jun; ():1-15. PubMed ID: 38842367
[TBL] [Abstract][Full Text] [Related]
4. Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review.
Vulto AG; Vanderpuye-Orgle J; van der Graaff M; Simoens SRA; Dagna L; Macaulay R; Majeed B; Lemay J; Hippenmeyer J; Gonzalez-McQuire S
Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33213079
[TBL] [Abstract][Full Text] [Related]
5. An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain.
Barcina Lacosta T; Vulto AG; Huys I; Simoens S
Front Med (Lausanne); 2022; 9():1029040. PubMed ID: 36703896
[TBL] [Abstract][Full Text] [Related]
6. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.
Barbier L; Simoens S; Soontjens C; Claus B; Vulto AG; Huys I
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073861
[TBL] [Abstract][Full Text] [Related]
7. Key drivers for market penetration of biosimilars in Europe.
Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
[No Abstract] [Full Text] [Related]
8. Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term Gain.
Barcina Lacosta T; Vulto AG; Turk F; Huys I; Simoens S
BioDrugs; 2024 May; 38(3):325-329. PubMed ID: 38407791
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of biosimilar uptake in emerging markets.
Chhabra H; Mouslim MC; Kashiramka S; Rathore AS
Expert Opin Biol Ther; 2022 Jun; 22(6):679-688. PubMed ID: 35535988
[TBL] [Abstract][Full Text] [Related]
10. Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
Mestre-Ferrandiz J; Czech M; Smolen JS; Cornes P; Aapro MS; Danese S; Deitch S; Tyldsley H; Foster W; Shah P; Latymer M; Vulto AG
Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):509-519. PubMed ID: 38284223
[TBL] [Abstract][Full Text] [Related]
11. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
[TBL] [Abstract][Full Text] [Related]
12. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
Vogler S; Schneider P; Zuba M; Busse R; Panteli D
Front Pharmacol; 2021; 12():625296. PubMed ID: 34248615
[No Abstract] [Full Text] [Related]
13. Maximizing the benefits of using biosimilars in Egypt.
Fasseeh AN; Elezbawy B; El-Fass KA; GamaI M; Seyam A; Hayek N; Abdel Rahman N; Abdelhamid S; Fasseeh N; Saad AS; Elagamy A; Mahmoud A; Sedrak AS; Elshazly K; Eldebeiky M; Talaat M; Mohamed NM; Abdelaziz RA; Refaat R; Akeel S; Abaza S; Kaló Z
J Pharm Policy Pract; 2023 Jun; 16(1):79. PubMed ID: 37365620
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis.
Barcina Lacosta T; Vulto AG; Huys I; Simoens S
Front Pharmacol; 2022; 13():1031910. PubMed ID: 36588696
[No Abstract] [Full Text] [Related]
15. The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries.
Klein K; Gencoglu M; Heisterberg J; Acha V; Stolk P
BioDrugs; 2023 Mar; 37(2):235-245. PubMed ID: 36472773
[TBL] [Abstract][Full Text] [Related]
16. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.
Rémuzat C; Kapuśniak A; Caban A; Ionescu D; Radière G; Mendoza C; Toumi M
J Mark Access Health Policy; 2017; 5(1):1307315. PubMed ID: 28740617
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
[No Abstract] [Full Text] [Related]
18. Market diffusion of biosimilars in off-patent biologic drug markets across Europe.
Böhm AK; Steiner IM; Stargardt T
Health Policy; 2023 Jun; 132():104818. PubMed ID: 37086662
[TBL] [Abstract][Full Text] [Related]
19. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
[TBL] [Abstract][Full Text] [Related]
20. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
